Éolia Brissot

5.8k total citations
130 papers, 1.8k citations indexed

About

Éolia Brissot is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Éolia Brissot has authored 130 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Hematology, 41 papers in Oncology and 33 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Éolia Brissot's work include Hematopoietic Stem Cell Transplantation (65 papers), Acute Myeloid Leukemia Research (30 papers) and Acute Lymphoblastic Leukemia research (30 papers). Éolia Brissot is often cited by papers focused on Hematopoietic Stem Cell Transplantation (65 papers), Acute Myeloid Leukemia Research (30 papers) and Acute Lymphoblastic Leukemia research (30 papers). Éolia Brissot collaborates with scholars based in France, Italy and Israel. Éolia Brissot's co-authors include Mohamad Mohty, Florent Malard, Béatrice Gaugler, Pierre Brissot, Olivier Loréal, Bipin N. Savani, Marie‐Bérengère Troadec, Patrice Chevallier, Marc Grégoire and Rémy Duléry and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer.

In The Last Decade

Éolia Brissot

112 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Éolia Brissot France	25	1.1k	514	415	325	299	130	1.8k
Francesc Fernández‐Avilés Spain	24	1.2k 1.1×	532 1.0×	440 1.1×	239 0.7×	184 0.6×	89	1.8k
Byung‐Sik Cho South Korea	24	1.5k 1.4×	560 1.1×	580 1.4×	459 1.4×	362 1.2×	189	2.3k
Noriko Doki Japan	18	894 0.8×	324 0.6×	278 0.7×	233 0.7×	393 1.3×	181	1.5k
Filippo Milano United States	25	1.4k 1.3×	752 1.5×	424 1.0×	371 1.1×	250 0.8×	124	2.3k
Jaime Sanz Spain	27	1.6k 1.5×	791 1.5×	460 1.1×	418 1.3×	278 0.9×	191	2.5k
Ali Ünal Türkiye	23	835 0.8×	369 0.7×	322 0.8×	160 0.5×	242 0.8×	125	2.1k
Bin Cho South Korea	20	737 0.7×	316 0.6×	252 0.6×	381 1.2×	255 0.9×	168	1.7k
Carmen Di Grazia Italy	24	1.4k 1.3×	638 1.2×	555 1.3×	368 1.1×	120 0.4×	63	2.1k
Shigeo Fuji Japan	24	920 0.9×	536 1.0×	672 1.6×	213 0.7×	149 0.5×	151	1.9k
Rajat Kumar Canada	20	793 0.7×	324 0.6×	194 0.5×	245 0.8×	202 0.7×	182	1.4k

Countries citing papers authored by Éolia Brissot

Since Specialization

Citations

This map shows the geographic impact of Éolia Brissot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éolia Brissot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éolia Brissot more than expected).

Fields of papers citing papers by Éolia Brissot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éolia Brissot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éolia Brissot. The network helps show where Éolia Brissot may publish in the future.

Co-authorship network of co-authors of Éolia Brissot

This figure shows the co-authorship network connecting the top 25 collaborators of Éolia Brissot. A scholar is included among the top collaborators of Éolia Brissot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éolia Brissot. Éolia Brissot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bazarbachi, Ali, Jacques‐Emmanuel Galimard, Gérard Socié, et al.. (2025). Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP. American Journal of Hematology. 100(8). 1374–1386.

Gras, Emmanuelle, Patricia Monzó, Carolina García‐Vidal, et al.. (2025). Risk factors for invasive mould infections in adult patients with hematological malignancies and/or stem cell transplant: A systematic literature review and meta-analysis. Journal of Infection. 91(3). 106574–106574. 1 indexed citations

Sanz, Jaime, Myriam Labopin, Jurjen Versluis, et al.. (2025). Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT. Bone Marrow Transplantation. 60(4). 529–534.

Sadowska‐Klasa, Alicja, Jan Maciej Zaucha, Myriam Labopin, et al.. (2024). Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL—a report from the EBMT registry. Bone Marrow Transplantation. 59(3). 387–394.

Brissot, Éolia, Myriam Labopin, Hélène Labussière, et al.. (2024). Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. Blood Cancer Journal. 14(1). 31–31. 12 indexed citations

Malagola, Michele, Mirko Farina, Nicola Polverelli, et al.. (2024). Donor Lymphocyte Infusion in the Treatment of Post-Transplant Relapse of Acute Myeloid Leukemias and Myelodysplastic Syndromes Significantly Improves Overall Survival: A French–Italian Experience of 134 Patients. Cancers. 16(7). 1278–1278. 1 indexed citations

Paviglianiti, Annalisa, Joël Gozlan, Éolia Brissot, et al.. (2024). Human herpesvirus type 6 reactivation after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide and antithymocyte globulin: risk factors and clinical impact. PubMed. 6(1). 26–38. 1 indexed citations

Piemontese, Simona, Myriam Labopin, Goda Choi, et al.. (2024). Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide. Leukemia. 38(9). 2016–2022. 1 indexed citations

Duléry, Rémy, Florent Malard, Éolia Brissot, et al.. (2023). Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation. Bone Marrow Transplantation. 58(11). 1215–1222. 13 indexed citations

10.

Loke, Justin, Myriam Labopin, Charles Craddock, et al.. (2022). Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. Cancer. 128(15). 2922–2931. 31 indexed citations

11.

Quignon, Frédérique, et al.. (2022). Methyl-qPCR: a new method to investigate Epstein–Barr virus infection in post-transplant lymphoproliferative diseases. Clinical Epigenetics. 14(1). 33–33. 5 indexed citations

12.

Nagler, Arnon, Myriam Labopin, Xiao‐Jun Huang, et al.. (2022). Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplantation. 57(4). 572–578. 4 indexed citations

13.

Rialland, Fanny, Audrey Grain, Myriam Labopin, et al.. (2022). Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial. Bone Marrow Transplantation. 57(11). 1698–1703.

14.

Genthon, Alexis, Thibault Chiarabini, Nadia Valin, et al.. (2021). Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy. Leukemia & lymphoma. 62(6). 1502–1505. 9 indexed citations

15.

Brissot, Éolia, Marie‐Bérengère Troadec, Olivier Loréal, & Pierre Brissot. (2021). Iron and platelets: A subtle, under‐recognized relationship. American Journal of Hematology. 96(8). 1008–1016. 28 indexed citations

16.

Brissot, Éolia, Myriam Labopin, Domenico Russo, et al.. (2020). Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation. 55(9). 1763–1772. 15 indexed citations

17.

Stocker, Nicolas, Rémy Duléry, Giorgia Battipaglia, et al.. (2019). Impact of cyclosporine A concentration on acute graft‐vs‐host disease incidence after haploidentical hematopoietic cell transplantation. European Journal Of Haematology. 103(1). 10–17. 13 indexed citations

18.

Labopin, Myriam, Simona Lapusan, Françoise Isnard, et al.. (2017). Fractionated Gemtuzumab Ozogamicin in Association with High Dose Chemotherapy: A Bridge to Allogeneic Stem Cell Transplantation in Refractory and Relapsed Acute Myeloid Leukemia?. Blood. 130. 4603–4603. 1 indexed citations

19.

Mohty, Razan, Annalisa Ruggeri, Giorgia Battipaglia, et al.. (2016). CD34+ Selected Cells "Boost" for Poor Graft Function Post Allogeneic Stem Cell Transplantation. Blood. 128(22). 2300–2300.

20.

Péterlin, Pierre, Jacques Delaunay, Thierry Guillaume, et al.. (2014). Complete Donor T Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced-Intensity Conditioning Regimen Allogeneic Transplantation in Adults. Biology of Blood and Marrow Transplantation. 21(1). 180–184. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact